CN114568699A - Composition containing galacto-oligosaccharides and probiotics and application thereof - Google Patents
Composition containing galacto-oligosaccharides and probiotics and application thereof Download PDFInfo
- Publication number
- CN114568699A CN114568699A CN202011376993.4A CN202011376993A CN114568699A CN 114568699 A CN114568699 A CN 114568699A CN 202011376993 A CN202011376993 A CN 202011376993A CN 114568699 A CN114568699 A CN 114568699A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- infantis
- bifidobacterium longum
- infants
- probiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003271 galactooligosaccharides Chemical class 0.000 title claims abstract description 70
- 235000021255 galacto-oligosaccharides Nutrition 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000006041 probiotic Substances 0.000 title claims abstract description 22
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 22
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 49
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 49
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 33
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 28
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 28
- 230000035755 proliferation Effects 0.000 claims abstract description 23
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims description 18
- 235000016709 nutrition Nutrition 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims 1
- 229940004120 bifidobacterium infantis Drugs 0.000 abstract description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052799 carbon Inorganic materials 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 3
- 241000186000 Bifidobacterium Species 0.000 description 25
- 230000000968 intestinal effect Effects 0.000 description 24
- 235000013350 formula milk Nutrition 0.000 description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 210000000481 breast Anatomy 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 238000004321 preservation Methods 0.000 description 9
- 235000020256 human milk Nutrition 0.000 description 8
- 235000013406 prebiotics Nutrition 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000004251 human milk Anatomy 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 206010051606 Necrotising colitis Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 5
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000013618 yogurt Nutrition 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 244000005709 gut microbiome Species 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 235000020219 prebiotic milk Nutrition 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 206010011469 Crying Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108010000231 Choloylglycine hydrolase Proteins 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000538 anti-polioviral effect Effects 0.000 description 1
- 230000002953 anti-rotaviral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000003031 feeding effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 235000020615 partially hydrolysed formula Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000020192 probiotic milk Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000006098 transglycosylation Effects 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a composition containing galacto-oligosaccharides and probiotics and application thereof. The probiotics in the composition containing galactooligosaccharides and probiotics are bifidobacterium animalis BB12 and bifidobacterium longum subsp. The invention also provides application of the composition in promoting the proliferation of bifidobacterium longum subspecies infantis GB-1496. The research of the invention finds that the GOS is taken as a carbon source, the complex bifidobacterium animalis BB12 and bifidobacterium longum subsp infantis GB-1496 are adopted to obviously promote the proliferation of the bifidobacterium infantis, and the proliferation amount is obviously higher than that of a single combination of the GOS and the bifidobacterium animalis BB12 or the bifidobacterium longum subsp infantis GB-1496. Furthermore, with the combination of GOS, Bifidobacterium animalis BB12 and Bifidobacterium longum subspecies infantis GB-1496, Bifidobacterium longum subspecies infantis GB-1496 showed a predominant proliferation.
Description
Technical Field
The invention relates to a composition containing galacto-oligosaccharides and probiotics and application thereof, belonging to the technical field of health-care food.
Background
The intestinal system of the human body contains a large amount of bacteria, the total amount of which is more than 100 times of the cells of the human body, and the bacteria form the intestinal microecology of the human body. More and more studies indicate that the intestinal micro-ecology is closely related to the disease health of the human body, and especially the intestinal micro-ecology in the early life has an important influence on the health of life [1 ].
Previous studies have shown that different feeding regimes have a significant impact on the intestinal micro-ecology in infants in early stages. The ratio of bifidobacteria to lactobacilli in the faeces of the infants in the formula-fed group was significantly lower than that of the infants in the breast-fed group. By adding probiotics and prebiotics to infant formula milk powder, the intestinal micro-ecology of infants can be regulated, which is close to the intestinal micro-ecology constitution of breast-fed infants, especially the proportion of bifidobacteria [2 ].
BB12, bifidobacterium strain 12 belonging to the genus bifidobacterium animalis, is also one of the most widely used probiotics in research history and product applications. BB-12 is resistant to gastric acid and bile and can survive at pH2, mainly because BB12 has a gene encoding bile salt hydrolase, which hydrolyzes bound bile salts in the intestinal tract to form amino acids and free bile acids [4 ]. There have been a number of studies demonstrating that BB-12 survives through the gastrointestinal tract, and that BB-12 was detected in the feces at 6 weeks when a full-term infant was fed a partially hydrolyzed whey formula supplemented with BB-12[5 ]. BB-12 or BB-12+ galactooligosaccharides were detected in the feces of the subjects one week after consumption by healthy adults [6 ]. The adult eats yogurt containing BB-12 and inulin for 4 weeks, the level of BB-12 in feces is significantly higher than that of the control group, and 90% of BB-12 is live bacteria [7 ]. Clinical trials have shown that BB12 has good safety and tolerability among children 1-5 years of age [8], healthy adults recently treated with antibiotics [9], and women from early pregnancy to lactation [10 ].
There are a number of clinical studies reporting various benefits to the human body. First BB12 may provide intestinal comfort. Supplementation of colic infants with BB12(10^9 cfu/day) reduced crying time by more than 50% more than the control group [11 ]. BB-12 was added to a low lactose partially hydrolysed formula to feed infants with hernia for 1 month, with crying in the intervention group being significantly less persistent than in the control group and with all parameters of the quality of life (QOL) questionnaire significantly improved [12 ]. For elderly and healthy adults in nursing homes, BB-12 supplementation increases intestinal motility [37] and frequency of defecation, especially inadequate gastrointestinal symptoms for hospital visits [38 ]. Secondly, the administration of BB12 is beneficial for immune health. The milk powder added with BB-12 has a preventive effect on acute diarrhea [39], and domestic clinical experiments show that compared with the treatment effects of BB-12, bacillus subtilis dual live bacteria (momei) and a blank control group in children diarrhea patients, the results show that the BB-12 is effective in treatment, and the effect has no significant difference with momei [40 ]. Study of milk powder supplemented with BB12(10^6cfu) partially hydrolysed whey protein in healthy term infants resulted in an increase in fecal IgA total in formula-fed infants delivered vaginally. Anti-rotavirus specific IgA was also elevated in formula fed infants delivered by caesarean section, and anti-poliovirus specific IgA was elevated in faeces of all probiotic supplemented infants [41 ]. The preterm infants were fed milk powder containing BB12 (1.6X 10^9 on the first three days, 4.8X 10^9cfu on the fourth day) with fecal pH significantly lower than placebo. Infants have elevated short chain fatty acids in their stools and lower calprotectin levels, while the group has higher fecal IgA levels compared to the placebo group [43 ]. BB-12 maintained the gastrointestinal flora health of preterm infants who had been subjected to BB-12 for 3 weeks, both by fluorescence in situ hybridization and bacterial culture, and was found to significantly increase the number of intestinal bifidobacteria while decreasing the number of enterobacteria and clostridia [44 ]. Long-term follow-up of newborns supplemented with BB-12 after birth found that respiratory infections were significantly lower in infants at 8 months than in the control group [45], and still significantly lower at 2 years [46 ]. The addition of the yogurt ice of milk BB12 and the yogurt bag BB12 before the fermentation process of the common yogurt ice and the common yogurt ice for healthy adults can improve IL-2 secretion and NK cytotoxicity, and the number of upper respiratory tract infection fever days is small [47 ]. Third, BB please benefit oral health. Infants were given BB12 tablets (10^10 cfu/day) from 1-2 months to 2 years of age, and the number of oral mutans streptococci was assessed at 8 months with the lowest in BB12 group [48 ].
The breast milk not only contains rich nutrient substances, but also contains live microbial flora. For breast-fed infants, breast milk microecology is a key contributing factor to the development of intestinal microecology in infants. The most abundant intestinal micro-ecology of breast-fed infants in the early stages of life is bifidobacteria. Further microbiological analysis tests show that the intestinal flora of breast-fed infants is different from that of adults and is rich in bifidobacterium infantis. Studies have shown that the efficacy of bifidobacterium infantis mainly includes the following aspects:
firstly, bifidobacterium infantis has strong capacity of utilizing HMO and has advantages in intestinal colonization, and unlike other bifidobacteria, the genome of bifidobacterium infantis contains more extensive genes [13-19] related to HMO transportation and metabolism, and in vitro studies, bifidobacterium infantis grows better than other strains in the presence of HMO [19,25], so the bifidobacterium infantis strain has unique advantages over other conventional probiotics. Bifidobacterium infantis is also able to metabolize the short-chain fatty acids produced which reduce intestinal pathogens and promote the growth and maturation of intestinal epidermal cells [36 ]. Short chain fatty acids, commonly known as acetate, propionate, butyrate and lactate, are beneficial to the integrity of intestinal epidermal cells, except for being absorbed by intestinal cells as an energetic substance [42 ].
Secondly, bifidobacterium infantis has an anti-inflammatory effect, intestinal inflammation of premature infants is an important cause of reducing Necrotizing Enterocolitis (NEC) of premature infants. Research on intestinal cells as a model shows that the bifidobacterium infantis can induce the intestinal cells to express anti-inflammatory cytokines [20-23], and rat animal experiments show that the addition of the bifidobacterium infantis can reduce the inflammation of NEC [24 ]. Bifidobacteria are often deficient in the gut of preterm infants [26] and the incidence of NEC in breast-fed preterm infants is significantly lower than in formula-fed infants [27 ]. Unlike the breast milk of term infants, the breast milk of preterm infants contains a higher concentration of fucosylated HMO [28 ]. Comparing the feeding effect of bifidobacterium infantis and bifidobacterium lactis added in the premature infant population, the result shows that the colonization ability of bifidobacterium infantis is stronger than that of bifidobacterium lactis no matter whether the formula is fed or breast-fed, and the group of the breast-fed infants added with bifidobacterium infantis is the group with the highest number of bifidobacterium faecalis [29 ]. A number of clinical studies have shown that the risk of NEC development can be reduced by the administration of Bifidobacterium infantis to preterm infants [31-35 ].
Finally, the advantage of adding bifidobacterium infantis is also reflected in the aspect of immunity, and in a full-term infant clinical study of Bengal, the number of bifidobacterium infantis in the intestinal tract of an infant is found to be positively correlated with the vaccine response in the early four months of life, namely the vaccine response has a higher index [30-31] when the number of bifidobacterium infantis is higher, and the trend still exists [31] in 2 years after birth, and the bifidobacterium infantis is supposed to be helpful for activating the immune function and the immunological memory function.
Prebiotics are a class of carbohydrates that are not digestible by the human body and interact with the intestinal flora in the host's gut to produce substances or effects that are beneficial to the host [3 ]. Currently, most studied prebiotics include: galacto-oligosaccharides, fructo-oligosaccharides, inulin, isomerized lactose, polydextrose, xylo-oligosaccharides, and the like.
The structure of Galactooligosaccharides (GOS) is such that 1-7 galactosyl groups are attached mainly by beta-1, 4-glycosidic bonds on the galactose side of lactose [49 ]. The heterooligosaccharide is obtained by converting beta-D-galactosidase through transglycosylation by taking disaccharide lactose as a reaction substrate, and is formed by combining galactose and glucose. The glucosyl and galactosyl in the GOS structure are connected by beta-1, 4-glycosidic bond, and the adjacent galactosyl is connected by beta-1, 3, beta-1, 4 and beta-1, 6-glycosidic bond, wherein the beta-1, 4-glycosidic bond is mainly connected, and the main part is oligogalactotriose, tetrasaccharide and a small amount of pentasaccharide, hexasaccharide and the like. In addition, the beta-D-galactosidase of some microorganisms can catalyze the hydrolysis of glucose and galactose, which are substrates, from lactose to synthesize galactooligosaccharides with beta-1, 3 and beta-1, 6 glycosidic linkages to link galactooligosaccharides with a different structure than lactose. Animal milk contains a small amount of GOS, human breast milk contains a little more than 50%, and the milk has important physiological effects on establishment of microbial flora in intestinal tracts of animals and infants in lactation.
The prebiotic effect of GOS has been validated in a number of clinical studies. First, as a prebiotic. GOS infant formula stimulates the growth of bifido-and lactobacilli in the intestine, with stool characteristics similar to breast-fed term infants [51-52 ]. Healthy persons over 50 years old were supplemented with 5gGOS per day to increase bifidobacteria in the feces [53 ]. In another study of healthy adults, the levels of Bifidobacterium faecalis were higher in humans with GOS than in placebo controls, especially after amoxicillin [54 ]. The combined use of GOS and a novel iron agent (half of the common iron agent in terms of iron content) can improve the number of the iron agent on intestinal flora, particularly bifidobacteria and lactobacilli, while the effect of preventing anemia is not significantly different from that of the common iron agent [55 ]. Administration of 15gGOS daily to obese pre-diabetic patients increased the number of bifidobacteria in the gut, but did not affect insulin sensitivity and associated energy metabolism [56 ]. GOS can improve defecation by regulating intestinal microecology. Elderly women with constipation problems (69-87 years old) take 9g GOS daily to relieve constipation and increase the number of defecation per week [57 ]. Addition of low levels of GOS (2.4g/l) to infant formulas can increase stool frequency, lower stool pH, and stimulate intestinal bifidobacteria and lactobacilli to levels found in breast-fed infants [58 ]. Another clinical study in infants has found that increasing GOS (4-8g/l) content can improve stool firmness in infants [60 ]. The addition of GOS (5g/L) to the two-stage formula has a positive effect on the bifidobacteria flora and stool firmness of the infants during the weaning supplementation period [59 ]. Second, GOS can stimulate and enhance immunity. Supplementation of older women (65-85 years old) with a combination of lactoferrin (1 g/day), GOS (2.64 g/day) and vitamin D (20ug vitamin D3/day) can improve immune regulation and reduce the risk of infection [61 ]. Healthy infants were fed prebiotic milk powder (scGOS: PDX ═ 1: 1) and at 6, 8, 10, and 12 months, the control formula group gained weight higher than the probiotic milk powder and breast milk groups. The duration of diarrhea, the number of constipation and the number of respiratory tract infections within 1 year of age were all significantly different, with the control formula > probiotic formula > breast milk group. Healthy infants (allergic problems in at least one parent) were recruited and fed prebiotic milk powder (4g/L, scGOS: PDX ═ 1: 1) at least once and on average at 48 weeks, with the prebiotic milk powder group being lower than the control formula group [62 ]. Fatigue is a predictor of cardiovascular events in end-stage renal disease (ESRD) patients receiving hemodialysis treatment. Immune and autonomic dysfunction in hemodialysis patients can be regulated by administering 50ml of a drink containing 10 mg of vitamin B1, 1.8 mg of vitamin B2, 15 mg of niacin, 10 mg of vitamin B6, 30 mg of vitamin B12, 0.5 mg of folic acid, 60 mg of vitamin C, 500 mg of carnitine, 30 mg of coenzyme Q10 (coenzyme Q10), 5g of natural galacto-oligosaccharide and 8 mg of zinc daily [63 ]. Fourth, consumption of 5g GOS per day increases calcium absorption in girls between 10 and 13 years of age, which may be mediated by intestinal microbiota, in particular bifidobacteria [64 ]. Fifth, healthy adults were supplemented with 1gGOS twice daily, and skin conditions, including skin dehydration status and wrinkle area, were improved [65 ].
Reference documents:
[1]Sommer F(1),
F.The gut microbiota--masters of host development and physiology.Nat Rev Microbiol.2013Apr；11(4):227-38.
[2]Adlerberth I,Wold AE.Establishment of the gut microbiota in Western infants.Acta Paediatr 2009；98:229-38.
[3]Gibson GR,Hutkins R,Sanders ME,Prescott SL,Reimer RA,Salminen SJ,Scott K,Stanton C,Swanson KS,Cani PD,Verbeke K,Reid G.Expert consensus document:The International Scientific Association for Probiotics and Prebiotics(ISAPP)consensus statement on the definition and scope of prebiotics.Nat Rev Gastroenterol Hepatol.2017 Aug；14(8):491-502.
[4]GARRIGUES C,JOHANSEN E,PEDERSEN M B.Complete genome sequence of Bifidobacterium animalis subsp.lactis BB-12,a widely consumed probiotic strain[J].J Bacteriol,2010,192(9):2467-2468.
[5]Holscher H D,Czerkies L A,Pamela C,et al.Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants:a randomized,double-blind,controlled trial[J].JPEN J Parenter Enteral Nutr,2012,36(1 Suppl):106S.
[6]Alander M,
J,Kneifel W,et al.Effect of galacto-oligosaccharide supplementation on human faecal microflora and on survival and persistence of Bifidobacterium lactis Bb-12 in the gastrointestinal tract[J].Int Dairy J,2001,11(10):817-825.
[7]Savard P,Lamarche B,Paradis M,et al.Impact of Bifidobacterium animalis subsp.lactis BB-12 and,Lactobacillus acidophilus LA-5-containing yoghurt,on fecal bacterial counts of healthy adults[J].Int J Food Microbio,2011,149(1):50-57.
[8]Tan T P,Ba Z,Sanders M E,et al.Safety of Bifidobacterium animalis Subsp.Lactis(B.lactis)Strain BB-12-Supplemented Yogurt in Healthy Children[J].J Pediatr Gastroenterol Nutr,2017,64(2):302-309.
[9]Merenstein D J,Tan T P,Molokin A,et al.Safety of Bifidobacterium animalis subsp.lactis(B.lactis)strain BB-12-supplemented yogurt in healthy adults on antibiotics:a phase I safety study.[J].Gut Microbes,2015,6(1):66-77.
[10]Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization:a double-blind placebo-controlled study.Clinical and Experimental Allergy,38,1342–1348.
[11]The therapeutic efficacy of Bifidobacterium animalis subsp.lactis BB-
in infant colic:A randomised,double blind,placebo-controlled trial.Aliment Pharmacol Ther.2019；00:1–11.
[12]Innovative Dietary Intervention Answers to Baby Colic.Pediatr Gastroenterol Hepatol Nutr.2017 Jun；20(2):100-106.
[13]Sela D,Chapman J,Adeuya A,Kim J,Chen F,Whitehead T,et al.Thegenome sequence of Bifidobacterium longum subsp.infantis reveals adaptations for milk utilization within the infant microbiome.Proc Natl Acad Sci.2008；105(48):18964.
[14]LoCascio R,Ninonuevo M,Freeman S,Sela D,Grimm R,Lebrilla C,et al.Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific,preferential consumption of small chain glycans secreted in early human lactation.J Agric Food Chem.2007；55(22):8914–9.
[15]Garrido D,Ruiz-Moyano S,Lemay DG,Sela DA,German JB,Mills DA:Comparative transcriptomics reveals key differences in the response to milk oligosaccharides of infant gut-associated bifidobacteria.Scientific reports.2015；5:1-7.
[16]Garrido D,Barile D,Mills DA.A molecular basis for bifidobacterial enrichment in the infant gastrointestinal tract.Advances in Nutrition:An International Review Journal.2012；3(3):415S–21S.
[17]Kim JH,An HJ,Garrido D,German JB,Lebrilla CB,Mills DA.Proteomic analysis of Bifidobacterium longum subsp.infantis reveals the metabolic insight on consumption of prebiotics and host glycans.PLoS One.2013；8(2):e57535.
[18]Garrido D,Ruiz-Moyano S,Mills DA.Release and utilization of N-acetyl-
glucosamine from human milk oligosaccharides by Bifidobacterium longum subsp.infantis.Anaerobe.2012；18(4):430–5.
[19]Ward R,
M,Mills D,Lebrilla C,German J.In vitro fermentability of human milk oligosaccharides by several strains of bifidobacteria.Mol Nutr Food Res.2007；51(11):1398–405.
[20]Chichlowski M,De Lartigue G,German JB,Raybould HE,Mills DA.Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function.J Pediatr Gastroenterol Nutr.2012；55(3):321–7.
[21]Meng D,Zhu W,Ganguli K,Shi HN,Walker WA.Anti-inflammatory effects of Bifidobacterium longum subsp infantis secretions on fetal human enterocytes are mediated by TLR-4 receptors.Am J Physiol Gastrointest Liver Physiol.2016 Oct 1；311(4):G744-G753.
[22]Pokusaeva K,Fitzgerald GF,van Sinderen D.Carbohydrate metabolism in
Bifidobacteria.Genes Nutr.2011；6(3):285–306.
[23]Ganguli K,Meng D,Rautava S,Lu L,Walker WA,Nanthakumar N.Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation.American Journal of Physiology-Gastrointestinal and Liver Physiology.2013；304(2):G132–41.
[24]Underwood MA,Arriola J,Gerber CW,Kaveti A,Kalanetra KM,Kananurak A,et al.Bifidobacterium longum subsp.infantis in experimental necrotizing enterocolitis:alterations in inflammation,innate immune response,and the microbiota.Pediatr Res.2014；76(4):326–33.
[25]Locascio RG,
MR,Kronewitter SR,et al.A versatile and scalable strategy for glycoprofiling bifidobacterial consumption of human milk oligosaccharides.Microb Biotechnol.2009；2:333–42.
[26]Westerbeek EA,van den Berg A,Lafeber HN,Knol J,Fetter WP,van Elburg RM.The intestinal bacterial colonisation in preterm infants:a review of the literature.Clin Nutr.2006；25:361–8.
[27]Meinzen-Derr J,Poindexter B,Wrage L,Morrow AL,Stoll B,Donovan EF.Role of human milk in extremely low birth weight infants’risk of necrotizing enterocolitis or death.J Perinatol.2009；29:57–62.
[28]De Leoz ML,Gaerlan SC,Strum JS,et al.Lacto-N-tetraose,fucosylation,and secretor status are highly variable in human milk oligosaccharides from women delivering preterm.J Proteome Res.2012；11:4662–72.
[29]Underwood MA,Kalanetra KM,Bokulich NA,Lewis ZT,Mirmiran M,Tancredi DJ,
Mills DA.A comparison of two probiotic strains of bifidobacteria in premature infants.J Pediatr.2013 Dec；163(6):1585-1591.
[30]M.Nazmul Huda,MS,Zachery Lewis,BS,Karen M.Kalanetra,et al.Stool Microbiota and Vaccine Responses of Infants.Pediatrics 2014；134:e362–e372.
[31]Jacobs SE,Tobin JM,Opie GF,et al.Probiotic effects on late-onset sepsis in very preterm infants:a randomized controlled trial.Pediatrics.2013；132:1055–62.
[32]Samanta M,Sarkar M,Ghosh P,Ghosh Jk,Sinha Mk,Chatterjee S.Prophylactic probiotics for prevention of necrotizing enterocolitis in very low birth weight newborns.J Trop Pediatr.2009；55:128–31.
[33]Lin HC,Su BH,Chen AC,et al.Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants.Pediatrics.2005；115:1–4.
[34]Fernández-Carrocera LA,Solis-Herrera A,Cabanillas-Ayón M,et al.Double-blind,randomised clinical assay to evaluate the efficacy of probiotics in preterm newborns weighing less than 1500 g in the prevention of necrotising enterocolitis.Arch Dis Child Fetal Neonatal Ed.2013；98:F5–9.
[35]Bin-Nun A,Bromiker R,Wilschanski M,et al.Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates.J Pediatr.2005；147:192–6.
[36]Puertollano E,Kolida S,Yaqoob P.Biological significance of short-chain fatty acid metabolism by the intestinal microbiome.Curr Opin Clin Nutr Metab Care.2014；17:139–44.
[37]Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents.A randomized,controlled trial.J Nutr Health Aging.2007 Jul-Aug；11(4):305-11.
[38]Effect of the probiotic strain Bifidobacterium animalis subsp.lactis,BB-
on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort:a randomised,double-blind,placebo-controlled,parallel-group trial.Br J Nutr.2015 Nov 28；114(10):1638-46.
[39]Acidified milk formula supplemented with bifidobacterium lactis:impact on infant diarrhea in residential care settings[J].J Pediatr Gastroenterol Nutr,2004,38(3):288-292.
[40] comparative study on clinical efficacy of bifidobacterium BB-12 in treating infantile diarrhea, Journal of Practical Pediatrics in China, Chinese Journal of Practical Pediatrics, stage 07 in 2017, ISSN: 1005-2224.
[41]Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants:a randomized,double-blind,controlled trial.JPEN J Parenter Enteral Nutr.2012 Jan；36(1Suppl):106S-17S.doi:10.1177/0148607111430817.
[42]Elamin,E.E.,A.A.Masclee,J.Dekker,H.J.Pieters,and D.M.Jonkers.2013.Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers.Journal of Nutrition 143:1872–1881.
[43]Effects of Bifidobacterium lactis Bb12 supplementation on body weight,fecal pH,acetate,lactate,calprotectin,and IgA in preterm infants.Pediatr Res.2008 Oct；64(4):418-22.
[44]Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants:a double-blind,placebo-controlled,randomized study[J].J Clin Microbiol,2006,44(11):4025-4031.
[45]Bifidobacterium animalis subsp.lactis BB-12in reducing the risk of infections in infancy.British Journal of Nutrition(2011),105,409–416
[46]Taipale T J,
K,Isolauri E,et al.Bifidobacterium animalis subsp.lactis BB-12in reducing the risk of infections in early childhood[J].Pediatr Res,2015,79(1-1):65.
[47]Consumption of Bifidobacterium animalis subsp.Lactis BB-12 impacts upper respiratory tract infection and the function of NK and T cells in healthy adults.Mol.Nutr.Food Res.2016,60,1161–1171.
[48]Bifidobacterium animalis subsp.lactis BB-12 Administration in Early Childhood:A Randomized Clinical Trial of Effects on Oral Colonization by Mutans Streptococci and the Probiotic.Caries Res 2012；46:69–77.
[49]Ackerman DL(1),Craft KM(1),Townsend SD(2).Infant food applications of complex carbohydrates:Structure,synthesis,and function.Carbohydr Res.2017 Jan 2；437:16-27.
[50]Newburg DS,Ko JS,Leone S,Nanthakumar NN.Human Milk Oligosaccharides and
Synthetic Galactosyloligosaccharides Contain 3'-,4-,and 6'-Galactosyllactose and Attenuate Inflammation in Human T84,NCM-460,and H4 Cells and Intestinal Tissue Ex Vivo.J Nutr.2016 Feb；146(2):358-67.
[51]Supplementation of milk formula with galacto-oligosaccharides improves intestinal micro-flora and fermentation in term infants.Chin.Med.J.2004 Jun；117(6).
[52]Low level of galacto-oligosaccharide in infant formula stimulates growth of intestinal Bifidobacteria and Lactobacilli.World J.Gastroenterol.2008 Nov 14；14(42).
[53]A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age.Br J Nutr.2012 May；107(10):1466-75.
[54]Exploring the effects of galacto-oligosaccharides on the gut microbiota of healthy adults receiving amoxicillin treatment.Br J Nutr.2014 Aug 28；112(4):536-46.
[55]Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome:a randomised controlled study in Kenyan infants.Gut.2017 Nov；66(11):1956-1967.
[56]Supplementation of Diet With Galacto-oligosaccharides Increases Bifidobacteria,but Not Insulin Sensitivity,in Obese Prediabetic Individuals.Gastroenterology.2017 Jul；153(1):87-97.
[57]Galacto-oligosaccharides relieve constipation in elderly people.Ann Nutr Metab.1998；42(6):319-27.
[58]Effects of infant formula containing galacto-oligosaccharides on the intestinal microflora in infants.Zhongguo Dang Dai Er Ke Za Zhi.2008 Oct；10(5):629-32.
[59]Galacto-oligosaccharides are bifidogenic and safe at weaning:a double-blind randomized multicenter study.J Pediatr Gastroenterol Nutr.2009 Jan；48(1):82-8.
[60]Tolerance of formulas containing prebiotics in healthy,term infants.J Pediatr Gastroenterol Nutr.2014Nov；59(5):653-8.
[61]Bovine Lactoferrin Enhances TLR7-Mediated Responses in Plasmacytoid Dendritic Cells in Elderly Women.Front Immunol.2018 Nov 20；9:2677.
[62]The effects of prebiotic supplementation on weight gain,diarrhoea,constipation,fever and respiratory tract infections in the first year of life.Journal of Paediatrics and Child Health 54(2018)875–880.
[63]Effects of Nutritional Supplementation on Fatigue,and Autonomic and Immune Dysfunction in Patients with End-Stage Renal Disease:A Randomized,Double-Blind,Placebo-Controlled,Multicenter Trial.PLoS ONE 10(3):e0119578.
[64]Galacto-oligosaccharides increase calcium absorption and gut bifidobacteria in young girls:a double-blind cross-over trial.Br J Nutr.2013 Oct；110(7):1292-303.
[65]Dietary galacto-oligosaccharides improve skin health:a randomized double blind clinical trial.Asia Pac J Clin Nutr.2017；26(4):613-618。
Disclosure of Invention
In order to solve the above technical problems, the present invention aims to provide a composition capable of promoting the proliferation of bifidobacterium longum subsp.
In order to achieve the above objects, the present invention provides a composition comprising galactooligosaccharides and probiotics, wherein the probiotics are bifidobacterium animalis BB12 and bifidobacterium longum subsp.
According to a particular embodiment of the invention, in the composition of the invention, said Bifidobacterium longum subsp. infantis GB-1496 is Bifidobacterium longum subsp. infantis with the collection number CCTCC No. m 2011122. The strain is preserved in China Center for Type Culture Collection (CCTCC) with the preservation unit address: wuhan university, Wuhan, China, 430072; the preservation date is as follows: 2011, 04 month 10 days; the preservation number is: CCTCC NO: m2011122, category naming: bifidobacterium longum subsp.
The bifidobacterium longum subspecies infantis CCTCC No. M2011122 has better free radical scavenging capacity and reducing capacity, and can induce Caco-2 cells to increase the expression of antioxidant enzymes, so the bifidobacterium longum subspecies infantis GB-1496 strain has an antioxidant activity effect, and can reduce the concentration of free radicals to inhibit organ aging.
According to a specific embodiment of the present invention, preferably, in the above composition, the ratio of viable count of bifidobacterium animalis BB12 and bifidobacterium longum subsp. 1; preferably 1: 1; or the colony number ratio of the bifidobacterium animalis BB12 to the bifidobacterium longum subspecies infantis GB-1496 is 1: 10-10: 1; preferably 1: 1.
according to a particular embodiment of the invention, preferably, in the above composition, the ratio of galactooligosaccharide, bifidobacterium animalis BB12 and bifidobacterium longum subsp. (106-1013)cfu：(106-1013) cfu; wherein, the quantity of the animal bifidobacterium BB12 and the bifidobacterium longum subspecies of infants GB-1496 is based on the colony number or the viable bacteria number.
According to a specific embodiment of the present invention, preferably, in the above composition, the content of the galactooligosaccharide is 0.01 to 50 g.
The composition of the present invention may be prepared by directly mixing galactooligosaccharide-containing bacteria with probiotics.
The invention also provides a nutritional composition comprising the composition containing galactooligosaccharides and probiotics. The nutritional composition may also contain other food or medicine raw materials, adjuvants, and additives. In the preparation of the nutritional composition, the composition containing galactooligosaccharides and probiotics may be directly mixed with other raw materials, adjuvants, additives.
The invention also provides a food product comprising the above galactooligosaccharide and probiotic-containing composition and/or the above nutritional composition. The food can be food for children or food for the elderly. According to a specific embodiment of the present invention, the food may include one or a combination of two or more of milk powder, supplementary food, beverage, etc., and may further include other raw materials, auxiliary materials, and additives that are allowed to be added.
The invention also provides application of the combination of galactooligosaccharide, bifidobacterium animalis BB12 and bifidobacterium longum subsp.infantis GB-1496 in promoting proliferation of the bifidobacterium longum subsp.infantis GB-1496.
The invention also provides application of the composition containing galactooligosaccharides and probiotics in promoting proliferation of bifidobacterium longum subsp.
According to a particular embodiment of the invention, preferably, the aforementioned promotion means promotion of the proliferation of Bifidobacterium longum subspecies infantis GB-1496 in the intestinal tract.
The invention also provides the application of the combination of galactooligosaccharide, bifidobacterium animalis BB12 and bifidobacterium longum subsp.infantis GB-1496 in promoting the proliferation of the bifidobacterium longum subsp.infantis GB-1496; preferably the application in promoting the colonization and proliferation of Bifidobacterium longum subspecies of infants GB-1496 in intestinal tract.
According to a particular embodiment of the invention, in several of the above applications, the ratio of galactooligosaccharide, bifidobacterium animalis BB12 and bifidobacterium longum subsp. (106-1013)cfu：(106-1013) cfu; wherein, the quantity of the animal bifidobacterium BB12 and the bifidobacterium longum subspecies of infants GB-1496 is based on the colony number or the viable bacteria number.
Bifidobacterium infantis is one of the earliest colonizing bifidobacteria in the infant's intestine. Finding an effective method for promoting the multiplication and the preferential multiplication of the bifidobacterium infantis in a synergistic way is very important for intestinal colonization and further playing other effects.
The study of the invention finds that the compound Bifidobacterium animalis BB12 and Bifidobacterium longum subspecies infantis GB-1496 are adopted to take GOS as a carbon source, so that the proliferation of Bifidobacterium infantis can be remarkably promoted, and the proliferation amount is remarkably higher than that of a single combination of GOS and Bifidobacterium animalis BB12 or Bifidobacterium longum subspecies infantis GB-1496. Furthermore, with the combination of GOS, Bifidobacterium animalis BB12 and Bifidobacterium longum subspecies infantis GB-1496, Bifidobacterium longum subspecies infantis GB-1496 showed a predominant proliferation.
Drawings
FIG. 1 shows the results of analysis of significant differences in the promotion of the proliferation of Bifidobacterium (OD600 values) when cultured using GOS as a carbon source and BB12, GB-1496 alone or a combination thereof.
FIG. 2 shows the results of PCR detection in the case of culturing using GOS as a carbon source, BB12, GB-1496 alone or a combination thereof.
Microbial deposits for patent procedures:
GB-1496 strain of the invention
The preservation date is as follows: 2011 10/04/month
The preservation unit: china Center for Type Culture Collection (CCTCC)
The address of the depository: wuhan university, Wuhan, China 430072
The preservation number is: CCTCC NO: m2011122
And (3) classification and naming: bifidobacterium longum subsp
Detailed Description
The technical solutions of the present invention will be described in detail below in order to clearly understand the technical features, objects, and advantages of the present invention, but the present invention is not limited to the practical scope of the present invention.
The bifidobacterium longum subspecies infantis GB-1496 is derived from human breast milk, is preserved in China Center for Type Culture Collection (CCTCC), and has the preservation unit address: wuhan university, Wuhan, China, 430072; the preservation date is as follows: 2011, 04 month 10 days; the preservation number is: CCTCC NO: m2011122, category naming: bifidobacterium longum subsp.
The taxonomical characteristics of the strain were confirmed based on the results of 16S rDNA sequence analysis and analysis by the API bacterial identification system. The morphological and general properties of Bifidobacterium longum subspecies infantis GB-1496 are detailed in Table 1.
TABLE 1
Bifidobacterium longum subsp. infantis GB-1496 strain is preserved at-80 deg.C in MRS culture medium containing 20% glycerol. Before use, the mixture was activated twice (24 hours) at 37 ℃ with MRS broth (DIFCO) containing 0.05% L-cysteine.
Examples of the experiments
(1) Preparing an MRS basic culture medium: weighing: weighing 5.0g of beef powder, 10.0g of tryptone, 4.0g of yeast powder, 801.0 mL of Tween and K2HPO4 2.0g、CH3COONa 5.0g、C6H5O7(NH4)3 2.0g、MgSO4 0.2g、MnSO40.05g, 15.0g of agar powder and 1000mL of distilled water. ② mixing uniformly: the weighed substances are uniformly mixed and heated while being uniformly stirred. Regulating the pH value: using 1 mol/mL-1Adjusting the pH value of the culture medium to 7.0-7.2 by NaOH. And fourthly, dissolving: pouring the dissolved culture medium into a triangular flask, adding a certain volume of water, and heating for dissolving. And (5) subpackaging: the prepared culture solution is poured into a 250mL triangular flask, and the mouth of the flask is wrapped by newspaper. Sixthly, sterilization: sterilizing the culture medium with high pressure steam for 15min, and cooling.
(2) Growth curves of GB-1496, BB12 and Recompositional bacteria (GB-1496: BB12 ═ 1: 1) in a GOS carbon source were compared for growth in MRS + 0.05% cysteine medium containing 1 wt% GOS, with the same culture initiation amounts. The results show that GB-1496 in combination with BB12 synergistically enhanced the increase in total bifidobacteria when GOS was used as the sole carbon source, with a significant difference between the three groups at 24 hours. Specific results are shown in fig. 1 and table 2, where in fig. 1, # indicates a difference from the pure BB12, # indicates a difference from the pure GB-1496, and GB-1496 and BB12 combined vs GB-1496: p < 0.01; combination of GB-1496 and BB12 vs BB12# #: p < 0.01.
As can be seen from fig. 1: in the case of GOS as a carbon source, the proliferation amount of the total amount of Bifidobacterium is significantly higher with the combination of GB-1496 and BB12 than with GB-1496 and BB12 alone.
TABLE 2
As can be seen from the data in table 2: on the premise of the same culture initiation amount, the proliferation amount obtained by using the mixed strain is 1.5 times of the half of the sum of the proliferation amounts obtained by culturing BB12 and GB-1496 alone, and the improvement is beyond expectation.
(3) PCR detection
In 24h, the proportion of the two bacteria in the compound bacteria is detected by a PCR method, and the primer design is based on a 16SrRNA sequence, so that the animal bifidobacteria and the infant bifidobacteria can be specifically distinguished.
Wherein, the primers for specifically distinguishing the bifidobacterium lactis are as follows:
Bani-tF：TCACGACAAGTGGGTTGCCA(SEQ ID NO：1)
Bani-tR：GTTGATCGGCAGCTTGCCG(SEQ ID NO：2)。
primers specifically distinguishing bifidobacterium longum subspecies of infants are as follows:
Binf-tF：ATCCGTCCGACCCAGACC(SEQ ID NO：3)
Binf-tR：CTCGACATCCTCACGGCC(SEQ ID NO：4)。
the results are shown in FIG. 2. As can be seen from fig. 2: in the mixed bacteria co-cultured with GB-1496 and BB12, Bifidobacterium longum subspecies neonatorum GB-1496 grows predominantly.
Example 1
The embodiment provides a composition containing GOS, bifidobacterium animalis BB12 and bifidobacterium longum subsp.infantis GB-1496, which contains the GOS, the bifidobacterium animalis BB12 and the bifidobacterium longum subsp.infantis GB-1496, wherein the ratio of GB-1496: BB12 ═ 1: 1.
example 2
This example provides a set of nutritional compositions comprising the composition provided in example 1 comprising GOS, bifidobacterium animalis BB12 and bifidobacterium longum subsp. The nutritional composition has remarkable effect in promoting proliferation of Bifidobacterium longum subspecies infantis GB-1496 in intestinal tract, and can make Bifidobacterium longum subspecies infantis GB-1496 show advantage growth.
Example 3
This example provides a group of baby foods comprising one or a combination of two of the compositions comprising GOS, bifidobacterium animalis BB12 and bifidobacterium longum subsp infantis GB-1496 and the nutritional compositions comprising GOS, bifidobacterium animalis BB12 and bifidobacterium longum subsp infantis GB-1496 as provided in example 1, wherein the compositions and nutritional compositions comprising GOS, bifidobacterium animalis BB12 and bifidobacterium longum subsp infantis GB-1496 may be added alone or in any combination and in any proportion. The food can be food for children or elderly people, such as milk powder, beverage, and infantile supplementary food.
The food has remarkable promoting effect on proliferation of Bifidobacterium longum subspecies infantis GB-1496 in intestinal tract, and can make Bifidobacterium longum subspecies infantis GB-1496 show advantage growth.
Example 4
The present example provides a group of medicaments, which respectively comprise one or two of the composition comprising GOS, bifidobacterium animalis BB12 and bifidobacterium longum subspecies infantis GB-1496 provided in example 1 and the nutritional composition comprising bifidobacterium longum subspecies infantis GB-1496 provided in example 2, wherein the composition and the nutritional composition comprising GOS, bifidobacterium animalis BB12 and bifidobacterium longum subspecies infantis GB-1496 can be added alone or in any combination and in any proportion.
The medicine has remarkable promoting effect on proliferation of Bifidobacterium longum subspecies infantis GB-1496 in intestinal tract, and can make Bifidobacterium longum subspecies infantis GB-1496 show advantage growth.
Sequence listing
<110> Inmunogu Yili industry group GmbH
<120> composition containing galactooligosaccharide and probiotics and application thereof
<130> GAI20CN7125
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Bani-tF
<400> 1
<210> 2
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Bani-tR
<400> 2
gttgatcggc agcttgccg 19
<210> 3
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Binf-tF
<400> 3
atccgtccga cccagacc 18
<210> 4
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Binf-tR
<400> 4
ctcgacatcc tcacggcc 18
Claims (10)
1. A composition comprises galactooligosaccharides and probiotics, wherein the probiotics are Bifidobacterium animalis BB12 and Bifidobacterium longum subsp.
2. The composition according to claim 1, wherein the ratio of viable count of bifidobacterium animalis BB12 and bifidobacterium longum subsp. 1; preferably 1: 1.
3. the composition according to claim 1 or 2, wherein the ratio of galactooligosaccharides, bifidobacterium animalis BB12 and bifidobacterium longum subsp. (106-1013)cfu：(106-1013)cfu；
Preferably, in the above composition, the content of the galactooligosaccharide is 0.01-50 g.
4. A nutritional composition comprising the composition according to any one of claims 1-3.
5. A food product comprising the composition of any one of claims 1-3 and/or the nutritional composition of claim 4;
preferably, the food is a pediatric food or an geriatric food;
preferably, the food comprises one or more of milk powder, complementary food and beverage.
6. A medicament comprising the composition of any one of claims 1-3 and/or the nutritional composition of claim 4.
7. Application of combination of galactooligosaccharide, bifidobacterium animalis BB12 and bifidobacterium longum subsp.infantis GB-1496 in promoting proliferation of bifidobacterium longum subsp.infantis GB-1496.
8. Use according to claim 7, wherein the ratio of galactooligosaccharides, Bifidobacterium animalis BB12 and Bifidobacterium longum subspecies infantis GB-1496 is 1 g: (106-1013)cfu：(106-1013)cfu。
9. Use of a composition comprising galactooligosaccharides and probiotics according to claim 1 for promoting proliferation of bifidobacterium longum subsp.
10. The use according to claim 7 or 9, wherein the promotion is in the promotion of proliferation of bifidobacterium longum subsp.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011376993.4A CN114568699B (en) | 2020-11-30 | 2020-11-30 | Composition containing galactooligosaccharides and probiotics and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011376993.4A CN114568699B (en) | 2020-11-30 | 2020-11-30 | Composition containing galactooligosaccharides and probiotics and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114568699A true CN114568699A (en) | 2022-06-03 |
| CN114568699B CN114568699B (en) | 2023-08-29 |
Family
ID=81767335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011376993.4A Active CN114568699B (en) | 2020-11-30 | 2020-11-30 | Composition containing galactooligosaccharides and probiotics and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114568699B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107212415A (en) * | 2017-05-18 | 2017-09-29 | 江西长通实业有限公司 | A kind of 5-linked probiotics nutrient powder and preparation method thereof |
| CN111067104A (en) * | 2019-12-30 | 2020-04-28 | 黑龙江省完达山乳业股份有限公司 | Composite probiotic infant formula milk powder and preparation method thereof |
-
2020
- 2020-11-30 CN CN202011376993.4A patent/CN114568699B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107212415A (en) * | 2017-05-18 | 2017-09-29 | 江西长通实业有限公司 | A kind of 5-linked probiotics nutrient powder and preparation method thereof |
| CN111067104A (en) * | 2019-12-30 | 2020-04-28 | 黑龙江省完达山乳业股份有限公司 | Composite probiotic infant formula milk powder and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| YI-HENG CHIUA，等: "Characterisation of bifidobacteria with immunomodulatory properties isolated from human breast milk", 《JOURNAL OF FUNCTIONAL FOODS》 * |
| 汪多仁: "《绿色医药化学品》", 31 July 2008, 科学技术文献出版社 * |
| 胡学智: "益生菌、益生元和消化酶", 《工业微生物》 * |
| 薛雅莺，等: "低聚半乳糖的特性及应用前景", 《发酵科技通讯》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114568699B (en) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10716321B2 (en) | Oligosaccharide mixture and food product comprising same | |
| RU2521500C2 (en) | USING STRAIN Bifidobacterium lactis CNCM I-3446 IN CHILDREN DELIVERED BY CESAREAN SECTION (VERSIONS) AND PROBIOTIC COMPOSITION CONTAINING ABOVE STRAIN (VERSIONS) | |
| EP2162020B1 (en) | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide | |
| RU2731067C2 (en) | Composition for use in improving stool consistence or frequency in infants or young children | |
| TW201302205A (en) | Composition for use in the preventing of acute respiratory tract infections and/or relieving symptoms of said infections | |
| TW201002216A (en) | Probiotics to improve gut microbiota | |
| WO2010002241A1 (en) | Nutritional composition for infants delivered via caesarean section | |
| MX2008011450A (en) | Synbiotic mixture. | |
| CN112741334B (en) | Prebiotic compositions, and uses thereof | |
| CN114568699B (en) | Composition containing galactooligosaccharides and probiotics and application thereof | |
| CN112806577B (en) | Prebiotic probiotic synergistic combinations for butyric acid production | |
| CN114568701B (en) | Composition containing fructo-oligosaccharide and probiotics and application thereof | |
| CN113841898A (en) | Prebiotic composition and application thereof in promoting growth of bifidobacterium longum subspecies of infants YLGB-1496 | |
| CN113862311A (en) | Application of combination of isomerized lactose and 2' -fucosyllactose in promoting acid production of Bifidobacterium longum infant subspecies metabolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |